Małkowski, M.; Chudek, A.; Almgren-Rachtan, A.; Chudek, J.T.; Chłosta, P.L.
Impact of Fixed-Dose Combination Versus Single-Component Therapy for Benign Prostatic Hyperplasia-Related Urinary Symptoms on Persistence, Adherence, and Satisfaction in a Real-Life Setting. Pharmaceuticals 2025, 18, 1439.
https://doi.org/10.3390/ph18101439
AMA Style
Małkowski M, Chudek A, Almgren-Rachtan A, Chudek JT, Chłosta PL.
Impact of Fixed-Dose Combination Versus Single-Component Therapy for Benign Prostatic Hyperplasia-Related Urinary Symptoms on Persistence, Adherence, and Satisfaction in a Real-Life Setting. Pharmaceuticals. 2025; 18(10):1439.
https://doi.org/10.3390/ph18101439
Chicago/Turabian Style
Małkowski, Mateusz, Anna Chudek, Agnieszka Almgren-Rachtan, Jerzy Tadeusz Chudek, and Piotr Ludwik Chłosta.
2025. "Impact of Fixed-Dose Combination Versus Single-Component Therapy for Benign Prostatic Hyperplasia-Related Urinary Symptoms on Persistence, Adherence, and Satisfaction in a Real-Life Setting" Pharmaceuticals 18, no. 10: 1439.
https://doi.org/10.3390/ph18101439
APA Style
Małkowski, M., Chudek, A., Almgren-Rachtan, A., Chudek, J. T., & Chłosta, P. L.
(2025). Impact of Fixed-Dose Combination Versus Single-Component Therapy for Benign Prostatic Hyperplasia-Related Urinary Symptoms on Persistence, Adherence, and Satisfaction in a Real-Life Setting. Pharmaceuticals, 18(10), 1439.
https://doi.org/10.3390/ph18101439
